Items Tagged ‘News’

April 21st, 2017

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed

By

Small, phase one trial of a dendritic cell vaccine supports further study in larger trials A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases, researchers at the Duke […]

View full entry

Tags: General, glioblastoma, immunotherapy, News, Other News Topics (not Types of Cancer)


April 19th, 2017

Combination Immunotherapy with Yervoy and Opdivo Improves Overall Survival Compared to Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

By

The first overall survival data from the CheckMate -067 clinical trial evaluating Yervoy (ipilumamab) and Opdivo (nivolumab) combinations has just been reported.  The two-year survival rates were 64% for the Opdivo plus Yervoy combination, 59% for Opdivo alone and 45% for Yervoy alone. About Opdivo Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is […]

View full entry

Tags: immunotherapy, Melanoma, News, opdivo, PD1


April 18th, 2017

Tagrisso Approved for Treatment of Certain Lung Cancers

By

The U.S. Food and Drug Administration granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. Lung cancer remains the leading […]

View full entry

Tags: immunotherapy, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, tagrisso


April 17th, 2017

Breast cancer rates increasing among Asian Americans

By

Researchers examined breast cancer incidence rates among seven Asian American ethnic groups in this new study.  In contrast to other US racial/ethnic groups, Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years. To better understand potential contributors to this increase, researchers at the Cancer Prevention Institute of California (CPIC) examined […]

View full entry

Tags: Breast Cancer, News


April 13th, 2017

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer

By

Treatment with the immune checkpoint inhibitor Opdivo (nivolumab) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data presented here at the AACR Annual Meeting in Washington DC this week. Lung cancer remains the leading cause of cancer-related deaths in the […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, Precision Medicine PD-1


April 12th, 2017

Tecentriq Plus Abraxane Results Suggest Novel Immunotherapy PD-1 “Checkpoint” Inhibitors Have Role in Management of Triple-Negative Breast Cancer

By

The investigative agent, Tecentriq (atezolizumb), in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. Approximately 10-20% of breast cancers are referred to as triple-negative breast cancer (TNBC). These types of cancers are both hormone-negative and HER2-negative. Hormone-negative breast cancer refers to a type of breast cancer […]

View full entry

Tags: Breast Cancer, News, precision medicine, Tecentriq, tnbc


April 4th, 2017

Keytruda Shows Promise in Treatment of Mesothelioma

By

Keytruda (pembrolizumab), an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published in The Lancet Oncology, is the first […]

View full entry

Tags: keytruda, Mesothelioma, News


April 3rd, 2017

Niraparib Approved for Ovarian Cancer Maintenance Treatment

By

Zejula (Niraparib) has been approved by the US Food and Drug Administration (FDA) for use as maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal who are in complete or partial response to platinum-based chemotherapy. Niraparib is a poly ADP-ribose polymerase (PARP) inhibitor, but unlike other drugs in this class, it […]

View full entry

Tags: News, niraparib, Ovarian Cancer, parp


March 31st, 2017

FDA Approves Bavencio as First Treatment for Merkel Cell Cancer

By

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC. According to the National Cancer Institute, approximately […]

View full entry

Tags: Bavencio, General, Merkel Cell Cancer, News, PD-1, Skin Cancer


March 28th, 2017

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant

By

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous stem cell transplant (ASCT). The expanded indication makes Revlimid® the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.1 Autologous stem cell transplant after […]

View full entry

Tags: maintenance, Multiple Myeloma, News, revlimid, secondary cancer, secondary malignancy


March 23rd, 2017

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers

By

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20 percent of cancers diagnosed worldwide. The trial is called DART, […]

View full entry

Tags: All Cancer Types, General, immunotherapy, keytruda, Neuroblastoma, News, Other News Topics (not Types of Cancer), Retinoblastoma, Sarcoma, Vaginal Cancer


March 22nd, 2017

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma

By

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma.  Patients with relapsed […]

View full entry

Tags: kyprolis, Multiple Myeloma, News, proteosome inhibitors


March 17th, 2017

Dealing with Distress

By

Why it’s important to acknowledge distress during cancer care and what to do about it By Teresa L. Deshields and Clorinda Walley The moment a patient is diagnosed with cancer, one symptom is likely to surface: distress. Sadness, fear, helplessness, anger, social concerns, depression, anxiety, panic – just about everyone that has cancer suffers distress […]

View full entry

Tags: General, general cancer, News


March 16th, 2017

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer

By

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical […]

View full entry

Tags: Breast Cancer, kisqali, Metastatic Breast Cancer, News, riboiclib, Stages II-III Breast Cancer


March 16th, 2017

Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation

By

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application of chemotherapy to the cancerous region can preserve limbs in a high percentage of these patients, researchers from five cancer centers in […]

View full entry

Tags: limb perfusion, News, Sarcoma